In the news: Lulu, SAS, ChannelAdvisor, Fujifilm Diosynth, Ribometrix, Aerie
From new executives to philanthropy and more, Triangle companies are making headlines. Here’s a roundup.
Read More
ribometrix
Inside potential $1B deal for Ribometrix: A look at startup’s science, history
Ribometrix, a Durham company specializing in RNA-based therapeutics, has formed a drug discovery and development collaboration with Genentech that could be worth more than $1 billion. Heres a look at the deal and the technology.
Read More
Durham biotech Ribometrix lands deal worth as much as $1B for RNA development
For the second time in less that two years Durham-based Ribometrix has landed a deal potentially work several hundred million dollars. This time, it’s even bigger – as much as $1 billion.
Read More
From a potential $700M deal to new funding, Durham’s Ribometrix is sizzling – and they are hiring
Durham startup Ribometrix is improving its corporate DNA with a series of big news announcements over the past week. From new funding to a new boarc chair and on Monday the biggest news of all – a development deal that could be worth $700 million. Oh, and they are hiring. NCBiotech Barry teater takes a look at what all is going on.
Read More
Durham startup Ribometrix lands $20M investment in drug development deal potentially worth $700M
Fresh off raising nearly $8 million in new capital, Durham-based Ribometrix announced a $20 million investment as part of a drug development deal with a Boston firm on Monday. And the deal could mean as much as $700 million to the biotech startup.
Read More
Durham biotech Ribometrix raises $7.8M, names new board chair
Ribometrix, a four-year-old startup focused on the use of ribonucleic acid, a nucleic acid present in all cells known as RNA, to target disease, has closed on another $7.8 million in venture funding.
Read More
Student, professor team up to fight cancer, other diseases with startup Ribometrix
The four-year-old startup that focuses on the use of ribonucleic acid, a nucleic acid present in all cells known as RNA, to target disease, recently closed on a $30 million Series A round.
Read More11 NC Biotech portfolio firms raise $26M; NC biotechs generate $962M in deals
Eleven bioscience companies that previously received loans from the Biotech Center raised about $26.3 million in follow-on funding from other sources in the quarter, according to research by the Biotech Center’s Life Science Intelligence staff.
Read More
Durham life science startup Ribometrix wraps up $30M funding round
Ribometrix, a three-year-old startup focused on the use of ribonucleic acid, a nucleic acid present in all cells known as RNA, to target disease, has closed on $30 million in new funding with two Triangle venture capital firms helping fuel the round.
Read More
